pdufa.bio
Home › Decisions › MRK 2026-06-12

MRK FDA decision — Jun 12, 2026

✓ APPROVED

Merck & Company Inc. — KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX ( · Clear Cell Renal Cell Carcinoma (ccRCC).

Run-up into the decision (T-120 → T+5)

PDUFA 6/12/26$123.93$100.6912/26/25
Daily close, T-120 (12/26/25) through T+5. Run-up high $123.93 on 2/26/26, low $100.69 on 12/26/25 (T-120 to T-1). FDA decision 6/12/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-06-12
OutcomeApproved
Drug / candidateKEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (
CompanyMerck & Company Inc.
120-day run-up (T-120→T-1)+19.9%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio